SINOPHARM: ANNOUNCEMENT CONTINUING CONNECTED TRANSACTIONS 2023 FINANCIAL SERVICES FRAMEWORK AGREEMENT
SINOPHARM: (1) CONTINUING CONNECTED TRANSACTIONS: 2023 PROCUREMENT FRAMEWORK AGREEMENT AND 2023 SALES FRAMEWORK AGREEMENT; (2) DISCLOSEABLE TRANSACTION AND CONTINUING CONNECTED TRANSACTION: 2023 FINANCIAL SERVICES FRAMEWORK AGREEMENT; (3) PROPOSED AMENDMEN
SINOPHARM: ANNOUNCEMENT (1) CONTINUING CONNECTED TRANSACTIONS: 2023 PROCUREMENT FRAMEWORK AGREEMENT, 2023 SALES FRAMEWORK AGREEMENT, 2023 EPC GENERAL CONTRACTING SERVICES FRAMEWORK AGREEMENT AND 2023 FACTORING SERVICES FRAMEWORK AGREEMENT; AND (2) DISCLOSE
SINOPHARM: CONTINUING CONNECTED TRANSACTIONS: ENTERING INTO THE 2022 PROCUREMENT FRAMEWORK AGREEMENT WITH NATONG GROUP COMPANY
SINOPHARM: CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PROCUREMENT AND SALES TRANSACTIONS: PROPOSED RATIFICATION OF THE 2021 ACTUAL TRANSACTION AMOUNTS AND PROPOSED REVISION OF THE ANNUAL CAPS FOR 2022 AND 2023 AND NOTICE OF EGM
SINOPHARM: DELAY IN DESPATCH OF CIRCULAR
SINOPHARM: (1) CONTINUING CONNECTED TRANSACTION: ENTERING INTO THE 2020 PROCUREMENT FRAMEWORK AGREEMENT; (2) DISCLOSEABLE TRANSACTION AND CONTINUING CONNECTED TRANSACTION: ENTERING INTO THE 2020 FINANCIAL SERVICES FRAMEWORK AGREEMENT; AND NOTICE OF EGM
SINOPHARM: (1) CONTINUING CONNECTED TRANSACTIONS: ENTERING INTO THE 2020 PROCUREMENT FRAMEWORK AGREEMENT, 2020 SALES FRAMEWORK AGREEMENT, 2020 EPC GENERAL CONTRACTING SERVICE FRAMEWORK AGREEMENT AND 2020 FACTORING SERVICES FRAMEWORK AGREEMENT; AND (2) DIS
SINOPHARM: UPDATE ANNOUNCEMENT ON CONNECTED TRANSACTION RELATING TO FORMATION OF A JOINT VENTURE COMPANY
SINOPHARM: CONTINUING CONNECTED TRANSACTIONS ENTERING INTO THE PROCUREMENT FRAMEWORK AGREEMENT WITH NATONG GROUP COMPANY
SINOPHARM: CONNECTED TRANSACTION FORMATION OF A JOINT VENTURE COMPANY
No Data